Completed PHASE3 INTERVENTIONAL NCT00266578

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial

Sponsor: Marc Rothenberg

Conditions Eosinophilic Esophagitis

Interventions Fluticasone Propionate

Updated 6 times since 2017 Last updated: Apr 10, 2013 Started: Oct 31, 2002 Primary completion: Nov 30, 2006 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Eosinophilic Esophagitis, this trial is completed. The trial is conducted by Marc Rothenberg and has accumulated 6 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marc Rothenberg

Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States